Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada. [More]
Study to measure and estimate global ablation market

Study to measure and estimate global ablation market

Reportbuyer.com has added a new market research report: Ablation Devices: Technologies and Global Markets. [More]
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern Medical Center faculty have received 19 grants totaling more than $26 million from the Cancer Prevention and Research Institute of Texas to expand cancer screenings, investigate the effectiveness and viability for cancer therapies and radiation treatments, conduct research into cancer biology, and recruitment. [More]
Vaccine boosts advanced NSCLC patient survival

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy. [More]
Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Preoperative ultrasound reveals NSCLC chest wall invasion

Preoperative ultrasound reveals NSCLC chest wall invasion

Surgeon-performed ultrasound is a good alternative to computed tomography for the identification of chest wall invasion in patients with non-small-cell lung cancer, suggests research demonstrating 90% sensitivity for detection of the spread. [More]
Widespread awareness, better treatment lower prostate cancer death rates

Widespread awareness, better treatment lower prostate cancer death rates

Fewer men are being diagnosed with and dying from prostate cancer these days. While that is due in part to widespread awareness and better treatment, it is also the result of more judicious screening. [More]
Scientists explore ways to personalise radiotherapy dose given to lung cancer patients

Scientists explore ways to personalise radiotherapy dose given to lung cancer patients

Manchester scientists are working out how to safely increase the radiotherapy dose given to lung cancer patients - potentially offering improved local control and survival. [More]
Advanced statistical approach evaluates gene-environmental interactions that contribute to disease

Advanced statistical approach evaluates gene-environmental interactions that contribute to disease

Dartmouth cancer researchers developed and tested an advanced statistical model to evaluate the genetic and environmental interactions that contribute to disease as published yesterday in Human Genetics. [More]
Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. [More]
Research to determine breath test's effectivness in patient with COPD

Research to determine breath test's effectivness in patient with COPD

NYU Langone Medical Center will lead a new clinical initiative -- funded by a $225,000 grant from The National Institutes of Health -- to determine a breath test's effectivness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstrutive pulmonary disease (COPD). [More]
Loyola’s free prostate cancer screenings on September 17

Loyola’s free prostate cancer screenings on September 17

As part of Prostate Cancer Awareness Month, Loyola University Medical Center will offer free prostate cancer screenings on Wednesday, Sept. 17. [More]
Current x-ray- examinations capture only 20% of lung cancer cases

Current x-ray- examinations capture only 20% of lung cancer cases

Each year, nearly 3000 Norwegians develop lung cancer. Current x-ray- examinations capture only 20 percent of cases. With modern ultralow-dose CT, the radiologists hit the bull's eye 90 per cent of the time. [More]
Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody. [More]
Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Researchers examine impact of BIM deletion on survival outcomes of advanced NSCLC patients

Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients. [More]

Pre-op PET/CT predicts stage I NSCLC adjuvant chemotherapy benefit

Preoperative imaging could help guide the use of postoperative adjuvant chemotherapy in patients with early non-small-cell lung cancer, Japanese researchers believe. [More]
Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show. [More]
Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have identified and characterized mutated forms of the gene that encodes BCR-ABL, the unregulated enzyme driving the blood cancer chronic myeloid leukemia (CML). [More]
EGFR biomarkers predict NSCLC response to vandetanib

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel. [More]